Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

August 11, 2020 05:33 AM EDTUpdated 10:30 AM

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech

Amber Tong

Senior Editor

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

A majority of pharma and biotech companies prohibit ChatGPT use, survey finds

Senate bill targeting WuXi won't affect federal spending, CBO says

GSK unveils long-term Shingrix data as shingles competition heats up

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech